AIM ImmunoTech, Inc. announced it has received notification from the FDA that the FDA’s Clinical Hold on AIM’s investigational new drug (IND) application for a Phase II study of Ampligen as a therapy for locally advanced pancreatic cancer has been lifted and the company may proceed with the study.
[AIM ImmunoTech, Inc.]
Sorry, but the selected Zotpress account can't be found.